What is VIP peptide? What the studies show
Reviewed 28 sourcesPublished by PepVault
VIP is a 28-amino-acid peptide your nerves make. What the COVID-19, lung and erectile trials found, its 1-minute half-life, and the CIRS nasal spray evidence.

- Last reviewed
- Sources
- 28
- Questions
- 7
- Compounds
- 1
The short answer
VIP (vasoactive intestinal peptide) is a 28-amino-acid messenger your nerves and immune cells make to relax blood vessels, open airways and calm inflammation. In blood, half of it is gone in about a minute. As a drug, aviptadil, it failed a 461-patient COVID-19 trial, is approved with phentolamine for erectile dysfunction in some countries, and its CIRS nasal spray rests mainly on one 20-patient open-label series.
Evidence: A well-mapped natural peptide with mixed human trial data: a large negative IV trial in COVID-19, small positive inhaled and lung studies, an approved erectile-dysfunction injection outside the U.S., and mainly one 20-patient open-label series for the CIRS nasal spray.

What is VIP peptide?
VIP stands for vasoactive intestinal peptide. Sami Said and Viktor Mutt isolated it from pig small intestine in 1970 and found a chain of 28 amino acids that widened blood vessels, lowered blood pressure, raised the heart's output and stimulated breathing1. They published its full sequence in 19742. Human VIP is the same chain, HSDAVFTDNYTRLRKQMAVKKYLNSILN, with an amide cap on its last amino acid3.
Despite the name, it is not only a gut hormone. VIP is made by nerves in the brain and throughout the body, and by immune cells, and it works as a neurotransmitter, a vessel relaxer, a trigger for gut and gland secretion, and an immune regulator4. It acts through two receptors on the cell surface, VPAC1 and VPAC24. Aviptadil is the drug name for synthetic VIP.
Its immune side is what drew the most attention. In mice with an arthritis that mimics rheumatoid arthritis, VIP injections cut how often and how badly the disease struck and prevented the joint and bone damage9. Results in mice often don't carry over to people, which is why the human trials below matter more.
Peptide SkySee VIP as a molecule53 peptides as a night sky in 3D. Each star opens into its molecule, one bead per amino acid, with the measured shape where one exists.Open the Peptide Sky
PepVault for iPhone
Keep your protocol in PepVault
PepVault tracks a nasal spray as its own kind of compound: a dose logs in one tap with no injection-site step, a twice-daily schedule counts both doses, and a reminder can fire at the dose time you set.
7 days free on the yearly plan for new subscribers.
How long does VIP last in the body?
Half of it is gone in about a minute. When four healthy volunteers were given VIP by IV drip, the level in their blood fell by half roughly every minute after the drip stopped6.
That one number explains how VIP has been given: as a continuous IV drip, an inhaled mist that puts it straight into the lungs, or an injection directly into the tissue that needs it. The nasal spray follows the same logic. Whether VIP sprayed in the nose reaches the human brain has not been measured; the only hint is from mice, where a VIP nasal spray improved memory in an Alzheimer's-like model27.
What did the COVID-19 trials of aviptadil find?
During the pandemic, aviptadil was tested as a way to protect the lungs in people sick enough to need oxygen or a ventilator. The largest and most independent trial was negative.
| Trial | Who and how | Main result |
|---|---|---|
| IV, 10 U.S. hospitals, 202210 | 196 people in respiratory failure; 3 days of IV aviptadil or placebo, 2 to 1 | Missed its main goal (alive and off respiratory failure at day 60; odds ratio 1.6, 95% CI 0.86 to 3.11). Survival at day 60 was better (odds ratio 2.0, p = 0.035), a secondary result |
| TESICO, 28 U.S. sites, NIH-funded, 202311 | 461 people with low blood oxygen, 94% in intensive care; 3 daily 12-hour IV infusions | No benefit: deaths by day 90 were 38% on aviptadil and 36% on placebo. Stopped early for futility |
| Inhaled, 9 centers in Turkey, 202512 | 80 people in hospital with COVID-19 pneumonia; inhaled aviptadil or placebo on top of standard care | Discharge at 7.8 vs 10 days on average (p = 0.049); lung CT improved more by day 28; deaths 5.1% vs 12.2% |
| Inhaled, planned for 5 European hospitals1314 | Planned 132 people at high risk of lung failure; 83 enrolled | Stopped in June 2023: too few COVID-19 patients left in hospital to enroll. No results posted |
| Inhaled ZYESAMI, U.S.15 | 144 enrolled | Terminated by the sponsor in 2021. No results posted |
Read together, the trials give a clear order of weight. TESICO was the biggest, was run and paid for by the National Institutes of Health (the developer supplied the drug), and found no difference in recovery or survival11. The 2022 trial's survival signal came after it had missed the outcome it was designed around, so it cannot settle the question on its own10. The inhaled trial is the one positive randomized result, but at 80 patients and a p-value just under 0.05 it needs repeating before anyone leans on it12.
What else has VIP been tested for?
Sarcoidosis. In an open phase 2 study, 20 people with active sarcoidosis, an immune disease that forms clumps of inflamed cells in the lungs, inhaled VIP for 4 weeks. It was well tolerated, and the lung cells washed out of their airways made less TNF-alpha, a key inflammatory signal, while regulatory T cells, the immune cells that calm other immune cells, increased16. The study measured immune markers, not symptoms, and had no placebo group.
Pulmonary hypertension. In 20 people with high blood pressure in the lungs, one inhaled 100 mcg dose during a heart catheter test widened the lung's blood vessels slightly and briefly, without lowering the pressure in the rest of the body or causing side effects17. The authors called the effect modest and short-lived17.
Asthma. In two groups of eight hospital patients recovering from a severe attack, a VIP drip raised peak airflow by 26 liters a minute after 30 minutes, against 39 with salbutamol, the standard rescue drug18. VIP opens airways, but less than the medicine people already use18.
The library's VIP page (pepvault.app/peptides/vip) links our study pages, including the asthma study and two of the COVID-19 trials.
Is VIP approved anywhere?
Yes, for one use and not in the United States. Invicorp is a single injection of 25 mcg aviptadil with 1 or 2 mg phentolamine, injected into the penis for erectile dysfunction21. The two halves do different jobs: phentolamine opens the arteries to let blood in, and VIP helps close off the veins that let it drain out21. It was approved in New Zealand by April 2000 and in the UK in October 200019. A newer UK licence, held by Evolan Pharma, dates from April 21, 201520, and Denmark's medicines agency published its risk plan in April 202223. Whether it is stocked in a given country changes over time.
In the trial the Welsh medicines body reviewed, 73% of 187 men reached a full erection with the combination against 83% with alprostadil, the standard injection, while it caused less pain and more facial flushing20. In a 2025 London clinic series of 308 men for whom alprostadil had failed or hurt, 59% found the combination worked, flushing was the most common side effect (22.5%), and one man (0.3%) had priapism, an erection that will not go down22.
In the U.S., as of November 2026 FDA has approved no product containing aviptadil: Drugs@FDA lists no application for it26. FDA's list of substances pharmacies have asked to compound puts vasoactive intestinal peptide in category 1, substances under evaluation, in its update of May 14, 202625. That is a step in a review, not an approval.
What is the VIP nasal spray for CIRS, and what is the evidence?
The nasal spray comes from one clinic's protocol for chronic inflammatory response syndrome (CIRS), an illness its proponents tie to time in water-damaged, moldy buildings. Its main published human evidence is one paper: Ritchie Shoemaker's 2013 series of 20 patients24. A 2017 report from the same group on brain-scan volumes appeared in a journal PubMed does not index28.
- Who: 20 adults whose CIRS had not resolved after an average of 36 months of the clinic's earlier treatment steps, which include leaving the moldy building24.
- What they took: aviptadil, 50 mcg by nasal spray four times a day at the start, then tapered down and back up as needed, for at least 18 months24. These are the study's doses, not a recommendation.
- What changed: symptom counts fell to the level of healthy controls, the inflammation markers the clinic tracks (C4a, TGF-beta1, MMP-9) were no longer different from controls by the end, and the rise in lung artery pressure during exercise fell back to normal within two months, by the paper's report24.
- Safety: no one stopped for side effects over 18 months, routine blood tests did not change, and one patient had a brief rise in lipase, a pancreas enzyme, that settled without stopping24.
The design limits what those numbers can prove. There was no placebo and no comparison group treated at the same time; patients were compared with the clinic's past patients and healthy controls. Every patient had also gone through every earlier treatment step, so the paper cannot separate VIP's effect from theirs. Five patients stopped VIP partway, and only their results while on it were counted. The clinic that ran the study also designed the protocol24. The paper says a placebo-controlled trial had begun; no result from one has been published. The nasal spray's evidence is promising in the patients who chose it and untested against placebo.
PepVault tracks a nasal spray as its own kind of compound: a dose logs in one tap with no injection-site step, a twice-daily schedule counts both doses, and a reminder can fire at the dose time you set. Set reminders in PepVault
What are the side effects of VIP?
VIP's side effects follow from what it does: it relaxes blood vessels. In healthy volunteers, the highest IV dose caused skin flushing and a faster pulse6, and in another study IV VIP raised heart rate and lowered the lower (diastolic) blood pressure number7. Flushing was the most common effect of the erectile injection too22. Inhaled in the lungs, a single dose did not lower blood pressure in the rest of the body17.
The clearest picture of too much VIP for too long comes from a rare tumor. A VIPoma pours VIP into the blood around the clock and causes heavy watery diarrhea, low potassium and flushing8. In the volunteer drip study, the higher doses briefly pushed blood levels into the VIPoma range, and those levels fell by half each minute once the drip stopped6. One lab finding pulls the other way from VIP's calming reputation: in human mast cells grown in a dish, VIP triggered them to release their contents, the same cells behind allergic reactions5.
Commonly reported: flushing, warmth or lightheadedness soon after a dose, mostly in the first days, which tends to settle; flushing and low blood pressure are more likely at higher doses.
In PepVault you can log a side effect such as flushing with a severity from 1 to 5, tied to the compound, so you can see whether it fades over the first weeks. Log it in PepVault
When to get help Lightheadedness that does not pass when you sit or lie down, fainting, or watery diarrhea that keeps going is a reason to contact your clinician.
Sources
- Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science. 1970. PubMed 5450698
- Mutt V, Said SI. Structure of the porcine vasoactive intestinal octacosapeptide. The amino-acid sequence. Eur J Biochem. 1974. PubMed 4829446
- UniProt P01282 (VIP_HUMAN): vasoactive intestinal peptide, residues 125-152, asparagine amide at 152. uniprot.org
- Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids. 2013. PubMed 22139413
- Kulka M et al. Neuropeptides activate human mast cell degranulation and chemokine production. Immunology. 2008. PubMed 17922833
- Domschke S et al. Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects. Gut. 1978. PubMed 730072
- Gill JS et al. Peptide histidine valine: its haemodynamic actions and pharmacokinetics in man differ from those of vasoactive intestinal peptide and peptide histidine methionine. Clin Sci. 1990. PubMed 2162275
- Vasoactive Intestinal Peptide-Secreting Tumor (VIPoma). Endotext, NCBI Bookshelf. PubMed 25905195
- Delgado M et al. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med. 2001. PubMed 11329057
- Youssef JG et al. The use of IV vasoactive intestinal peptide (aviptadil) in patients with critical COVID-19 respiratory failure: results of a 60-day randomized controlled trial. Crit Care Med. 2022. PubMed 36044317
- Brown SM et al. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. Lancet Respir Med. 2023. PubMed 37348524
- Esendagli D et al. Inhaled aviptadil is a new hope for recovery of lung damage due to COVID-19. Med Princ Pract. 2025. PubMed 39870064
- Boesing M et al. Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol. Trials. 2022. PubMed 36127739
- ClinicalTrials.gov NCT04536350: Inhaled aviptadil for the treatment of COVID-19 in patients at high risk for ARDS (terminated). clinicaltrials.gov
- ClinicalTrials.gov NCT04360096: Inhaled ZYESAMI (aviptadil acetate) for the treatment of severe COVID-19 (terminated). clinicaltrials.gov
- Prasse A et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med. 2010. PubMed 20442436
- Leuchte HH et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J. 2008. PubMed 18978135
- Morice AH, Sever PS. Vasoactive intestinal peptide as a bronchodilator in severe asthma. Peptides. 1986. PubMed 3529052
- Keijzers GB. Aviptadil (Senatek). Curr Opin Investig Drugs. 2001. PubMed 11566015
- All Wales Therapeutics and Toxicology Centre. AWMSG Secretariat Assessment Report: aviptadil/phentolamine mesilate (Invicorp) 25 micrograms/2 mg solution for injection. Reference 3435. May 2017. awttc.nhs.wales
- Dinsmore WW, Wyllie MG. Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction. BJU Int. 2008. PubMed 18485029
- Al-Mitwalli A et al. Intracavernosal injection of aviptadil and phentolamine for refractory erectile dysfunction. J Sex Med. 2025. PubMed 40192471
- Danish Medicines Agency. Summary of risk management plan for aviptadil/phentolamine mesylate, solution for injection, version 4.3. April 2022. laegemiddelstyrelsen.dk
- Shoemaker RC, House D, Ryan JC. Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings. Health. 2013;5(3):396-401. scirp.org
- FDA. Bulk drug substances nominated for use in compounding under section 503A of the FD&C Act, category 1 (updated May 14, 2026). fda.gov
- openFDA Drugs@FDA query for aviptadil (no matches, read November 20, 2026). api.fda.gov
- Cui X et al. Pharmacodynamics and toxicity of vasoactive intestinal peptide for intranasal administration. Pharmazie. 2013. PubMed 23444784
- Simon RA et al. Vasoactive intestinal polypeptide plasma levels associated with affective symptoms and brain structure and function in healthy females. Sci Rep. 2021 (its reference 44: Shoemaker R et al. Intranasal VIP safely restores volume to multiple grey matter nuclei in patients with CIRS. Int Med Rev. 2017;3). PubMed 33446759
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.